IGEV +/- Bortezomib (VelcadeTM) as induction before high dose consolidation in relapsed/ refractory Hodgkin's lymphoma after first line treatment : a randomized phase II trial

Trial Profile

IGEV +/- Bortezomib (VelcadeTM) as induction before high dose consolidation in relapsed/ refractory Hodgkin's lymphoma after first line treatment : a randomized phase II trial

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2014

At a glance

  • Drugs Bortezomib (Primary) ; Gemcitabine; Ifosfamide; Vinorelbine
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Sep 2010 Actual end date (February 2010) added as reported by ClinicalTrials.gov.
    • 01 Sep 2010 Planned end date changed from 1 Feb 2015 to 1 Feb 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top